Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 05, 2025 20:06 ET | Source: Robbins LLP

ZBIO Stock Notice: Zenas BioPharma, Inc. Stockholders are Encouraged to Contact Shareholder Rights Law Firm Robbins LLP for Information About the ZBIO Class Action

Robbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO
April 30, 2025 09:05 ET | Source: Helogen Corporation

Helogen Corporation Acquires Vellon Space to Expand Reach into India’s Space and Biotechnology Sectors

New York, NY, April 30, 2025 (GLOBE NEWSWIRE) -- Helogen Corporation, a space biology and infrastructure company, today announced the acquisition of Vellon Space Private Limited, a Bengaluru,...
April 16, 2025 16:13 ET | Source: Robbins LLP

Robbins LLP Reminds CERE Stockholders With Large Losses to Contact the Firm for Information About the Class Action Lawsuit on Behalf of Former Cerevel Therapeutics Holdings, Inc. Shareholders

Robbins LLP is Investigating Allegations that Cerevel Therapeutics Holdings, Inc. (formerly CERE) Misled Investors Relating to the Company's October 16, 20
April 07, 2025 14:46 ET | Source: Robbins LLP

SANA Stockholders Should Contact Shareholder Rights Law Firm Robbins LLP for Information on How to Lead the Class Action Against Sana Biotechnology, Inc.

Robbins LLP is Investigating Allegations that Sana Biotechnology, Inc. (SANA) Misled Investors Regarding its Ability to Maintain Operations.
March 17, 2025 19:05 ET | Source: Robbins LLP

Geron Corporation Shareholder Notice: Robbins LLP Reminds Investors of the Pending GERN Class Action Lawsuit

Robbins LLP is Investigating Allegations that Geron Corporation (GERN) Misled Investors Regarding the Launch and Potential Growth of Rytelo
March 04, 2025 07:30 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics Announces New Preclinical Data on Tumor-Selective Peptide-Drug Conjugates at ESMO Targeted Anticancer Therapies Congress 2025

Cybrexa presented new data from its clinical-stage alphalex™ peptide-drug conjugate technology at ESMO Targeted Anticancer Therapies Congress 2025.
February 13, 2025 20:27 ET | Source: Robbins LLP

Intellia Therapeutics, Inc. Shareholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against NTLA

Robbins LLP is Investigating Allegations that Intellia Therapeutics, Inc. (NTLA) Misled Investors Regarding the Viability of its Drug Candidate
February 13, 2025 19:52 ET | Source: Robbins LLP

Icon PLC Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Stockholders of the Class Action Against ICLR

Robbins LLP is Investigating Allegations that ICON PLC (ICLR) Misled Investors Regarding Demand
January 13, 2025 21:48 ET | Source: Robbins LLP

REGN Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors Class Action Against Regeneron Pharmaceuticals, Inc.

Robbins LLP is Investigating Allegations that Regeneron Pharmaceuticals, Inc. (REGN) Misled Investors Regarding its Business Prospects
January 08, 2025 18:38 ET | Source: Robbins LLP

Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Regeneron Pharmaceuticals, Inc. (REGN) Misled Investors Regarding its Business Prospects

Next Page keyboard_arrow_right